Facio-Scapulo-Humeral Dystrophy
13
5
5
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.7%
1 terminated out of 13 trials
83.3%
-3.2% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (13)
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Walking ANalysis Interest in Persons wiTh facioscapulohumEral Muscular Dystrophies
Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
FSHD Molecular Characterization
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI]
Computerized Facial Recognition for Automated Diagnosis of the Facio-Scapulo-Humeral Muscular Dystrophy (FSMHD)
Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD
Understanding Control and Mechanisms of Shoulder Instability in FSHD
Examination of Operative Approach in pwFSHD (Patient With Facioscapulohumeral Muscular Dystrophy)